In early stage disease, the I-SPY2 trial (NCT01042379) compared durvalumab plus olaparib and paclitaxel to paclitaxel alone as the preoperatory treatment for HER2-negative BC patients. The gene discussed is ERBB2; the disease is breast cancer.